Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/2/2024 | $7.00 | Outperform | Oppenheimer |
| 3/18/2024 | $6.00 | Outperform | Leerink Partners |
| 9/2/2021 | $2.00 | Overweight | Cantor Fitzgerald |
Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at American Society of Nephrology (ASN) Kidney Week On track for an End-of-Phase 1 meeting by year-end Ended third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026 SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company"
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment of 26 patients in the fourth cohort in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. "The completion of enrollment of our final cohort marks an important milestone as we near the end of our Phase 1b study. We have been pleased to see positive results from each of the prior three cohorts, showing c
SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 4, 2024, at 2:15 p.m. ETH.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Monday, September 9, 2024, at 10:00 a.m. ETThe live events and replays of the presentations will
10-Q - Regulus Therapeutics Inc. (0001505512) (Filer)
8-K - Regulus Therapeutics Inc. (0001505512) (Filer)
8-K - Regulus Therapeutics Inc. (0001505512) (Filer)
4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo Exploratory imaging analyses indicated reduction in total kidney volume in 70% of patients dosed with 3 mg/kg Fourth cohort enrollment underway Company to hold conference call at 8:30am ET today SAN DIEGO, June 24, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "R
Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the highest increases in PC1 and PC2 Cohort 3 fully enrolled with data readout anticipated in mid-2024; Cohort 4 screening to start in 2Q 2024 Company to hold conference call at 8:30am ET today SAN DIEGO, March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the second
Statistically significant increase in urinary polycystin 1(PC1) after treatment with RGLS8429 Urinary polycystin exhibits anticipated pharmacokinetics/pharmacodynamics (PK/PD) correlation in patients with ADPKD Company to hold conference call at 8:30 a.m. EDT today SAN DIEGO, Sept. 20, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the first cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
SC 13G/A - Regulus Therapeutics Inc. (0001505512) (Subject)
SC 13G - Regulus Therapeutics Inc. (0001505512) (Subject)
SC 13G/A - Regulus Therapeutics Inc. (0001505512) (Subject)
Oppenheimer initiated coverage of Regulus Therapeutics with a rating of Outperform and set a new price target of $7.00
Leerink Partners initiated coverage of Regulus Therapeutics with a rating of Outperform and set a new price target of $6.00
Cantor Fitzgerald initiated coverage of Regulus Therapeutics with a rating of Overweight and set a new price target of $2.00
4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $10 price target.
Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics (NASDAQ:RGLS) with a Buy and raises the price target from $11 to $28.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JP Morgan cut the price target for Sea Limited (NYSE:SE) from $84 to $78. JP Morgan analyst Ranjan Sharma downgraded the stock from Overweight to Neutral. Sea shares gained 0.6% to close at $75.89 on Monday. See how other analysts view this stock. Morgan Stanley raised the price target for Birkenstock Holding plc (NYSE:BIRK) from $44 to $58. Morgan Stanley analyst Edouard Aubin maintained an Equal-Weight rating. Birkenstock shares fell 2.8% to close at $59.78 on Monday. See how other analysts view
First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 R&D Day to discuss our ADPKD program to be held Wednesday, September 6th Strengthened leadership through appointments of Preston S. Klassen, M.D. as President and Head of Research & Development and Curtis A. Monnig, Ph.D. as Vice President of CMC SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate upd
SAN DIEGO, June 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced Preston S. Klassen, M.D., President and Head of Research & Development, has been appointed to the Company's Board of Directors. "We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD," said Stelios Papadopoulos, Ph.D., Chairman
Appoints Preston S. Klassen, M.D., as President and Head of Research & Development Curtis A. Monnig, Ph.D., named Vice President of CMC SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development. Dr. Klassen brings over 20 years of experience in leadership roles in both large and small biopharmaceutical companies. In addition, the Company announced the appointment of Curtis A. Monnig, Ph.D., to Vice President of